Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The ...